Capsulution NanoScience AG Positive Half-Year Results Following Significant Rise in Turnover
Berlin (July 29, 2004) - During the first half of the business year 2004 the Berlin-based technology company Capsulution NanoScience AG achieved a significant 130% rise in turnover compared to the same period last year. This time the EBIT of the first 6 months of the year was slightly positive compared with a loss of 0.6 million euros during the first half of 2003.

Alexander Herrmann, CFO of Capsulution, commented: "We are very delighted about the fact that our company, as one of very few in the area of nanotechnology, was able to generate a positive result over the past 12 months."

Despite the encouraging figures the first half of 2004 proceeded slightly below expectations. Capsulution plans to improve the result during the coming 6 months even further. A major contribution to that will come from the recently acquired renowned partners and customers for whom Capsulution is currently developing innovative nano-products.

Herrmann adds: "Our company too feels the enormous competitive pressure that our clients are up against, which often forces them to reduce costs. For those clients however that continue build on innovative product ideas we can offer just the right technology solutions. This is the mission we are continuing to adhere to in the future. To achieve this Capsulution uses proprietary resources to develop new building blocks to tap into new areas of application. We are confident that during the second half of 2004 we will be able to convince new industry partners of the usefulness and versatility of our nanotechnology approach. Of course we also continue to offer interested financiers the opportunity to invest in the successful progression of our technology development and to participate in the rapid increase of our company value."


280 words/1,742 characters


Capsulution NanoScience AG:
Capsulution NanoScience AG develops innovative nano- and micron-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. The capsules can be applied for the delivery of drugs, in cosmetic products, and in diagnostics. Today, the Berlin-based company has 16 highly qualified employees. Amongst Capsulution's clients and partners are key industry players such as Bayer AG, Gelita, SCA Hygiene Products, Cognis, OctoPlus and other renowned companies.

Download: Text as RTF file in www.biocommunications.net ("Presse Pool")

Further information:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D- 12489 Berlin, Germany
Tel.: +49-(0)30-63923627
Fax.: +49-(0)30-63923601
Web: www.capsulution.com
eMail: alexander.herrmann@capsulution.com 

© BIOCOMMUNICATIONS.net GmbH, Brunnenstr. 128, D-13355 Berlin, Germany